|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IER5L |
Gene summary for IER5L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IER5L | Gene ID | 389792 |
| Gene name | immediate early response 5 like | |
| Gene Alias | bA247A12.2 | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q5T953 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 389792 | IER5L | CCI_2 | Human | Cervix | CC | 3.34e-11 | 1.09e+00 | 0.5249 |
| 389792 | IER5L | sample1 | Human | Cervix | CC | 1.93e-10 | 6.19e-01 | 0.0959 |
| 389792 | IER5L | T1 | Human | Cervix | CC | 6.39e-27 | 7.77e-01 | 0.0918 |
| 389792 | IER5L | T2 | Human | Cervix | CC | 3.13e-03 | 4.85e-01 | 0.0709 |
| 389792 | IER5L | T3 | Human | Cervix | CC | 1.09e-02 | 2.39e-01 | 0.1389 |
| 389792 | IER5L | AEH-subject1 | Human | Endometrium | AEH | 1.13e-18 | 6.46e-01 | -0.3059 |
| 389792 | IER5L | AEH-subject2 | Human | Endometrium | AEH | 1.20e-14 | 5.26e-01 | -0.2525 |
| 389792 | IER5L | AEH-subject3 | Human | Endometrium | AEH | 5.70e-12 | 5.44e-01 | -0.2576 |
| 389792 | IER5L | EEC-subject2 | Human | Endometrium | EEC | 2.84e-02 | 3.50e-01 | -0.2607 |
| 389792 | IER5L | EEC-subject3 | Human | Endometrium | EEC | 9.34e-12 | -1.92e-01 | -0.2525 |
| 389792 | IER5L | GSM5276934 | Human | Endometrium | EEC | 1.19e-07 | -2.79e-01 | -0.0913 |
| 389792 | IER5L | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.41e-14 | -7.74e-02 | -0.1869 |
| 389792 | IER5L | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 7.39e-13 | -1.40e-01 | -0.1875 |
| 389792 | IER5L | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.71e-13 | -1.90e-01 | -0.1883 |
| 389792 | IER5L | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 5.75e-11 | -2.36e-01 | -0.1934 |
| 389792 | IER5L | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.45e-22 | 3.10e-01 | -0.1917 |
| 389792 | IER5L | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 5.67e-28 | 2.98e-01 | -0.1916 |
| 389792 | IER5L | LZE4T | Human | Esophagus | ESCC | 2.08e-06 | 3.87e-02 | 0.0811 |
| 389792 | IER5L | LZE5T | Human | Esophagus | ESCC | 8.24e-03 | 1.49e-01 | 0.0514 |
| 389792 | IER5L | LZE8T | Human | Esophagus | ESCC | 4.09e-02 | -5.08e-03 | 0.067 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IER5L | insertion | Nonsense_Mutation | novel | c.7_8insAATGAGGGAA | p.Cys3Ter | p.C3* | Q5T953 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| IER5L | deletion | Frame_Shift_Del | c.978delN | p.Gly328AlafsTer29 | p.G328Afs*29 | Q5T953 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |||
| IER5L | deletion | Frame_Shift_Del | c.978delC | p.Gly328AlafsTer29 | p.G328Afs*29 | Q5T953 | protein_coding | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| IER5L | SNV | Missense_Mutation | novel | c.26N>A | p.Ser9Asn | p.S9N | Q5T953 | protein_coding | tolerated_low_confidence(0.3) | benign(0.096) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IER5L | SNV | Missense_Mutation | novel | c.731C>G | p.Ser244Trp | p.S244W | Q5T953 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.984) | TCGA-NJ-A4YP-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| IER5L | SNV | Missense_Mutation | rs763398316 | c.34A>G | p.Ser12Gly | p.S12G | Q5T953 | protein_coding | deleterious_low_confidence(0.01) | benign(0.132) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |